title: Varicella zoster virus reactivation during or immediately following treatment of tegumentary leishmaniasis with antimony compounds.
abstract: Antimony compounds are the cornerstone treatments for tegumentary leishmaniasis. The reactivation of herpes virus is a side effect described in few reports. We conducted an observational study to describe the incidence of herpes zoster reactivation during treatment with antimony compounds. The global incidence of herpes zoster is approximately 2.5 cases per 1,000 persons per month (or 30 cases per 1,000 persons per year). The estimated incidence of herpes zoster in patients undergoing antimony therapy is higher than previously reported.
authors.affiliation: Hospital Universitário Júlio Müller, Universidade Federal de Mato Grosso, Cuiabá, MT, Brasil.
authors.forename: Andrea Barbieri
authors.initials: AB
authors.lastname: Barros
authors.affiliation: Hospital Universitário Júlio Müller, Universidade Federal de Mato Grosso, Cuiabá, MT, Brasil.
authors.forename: Alex Miranda
authors.initials: AM
authors.lastname: Rodrigues
authors.affiliation: Hospital Universitário Júlio Müller, Universidade Federal de Mato Grosso, Cuiabá, MT, Brasil.
authors.forename: Mariane Pereira
authors.initials: MP
authors.lastname: Batista
authors.affiliation: Hospital Universitário Júlio Müller, Universidade Federal de Mato Grosso, Cuiabá, MT, Brasil.
authors.forename: Sidney
authors.initials: S
authors.lastname: Munhoz Junior
authors.affiliation: Hospital Universitário Júlio Müller, Universidade Federal de Mato Grosso, Cuiabá, MT, Brasil.
authors.forename: Marcia
authors.initials: M
authors.lastname: Hueb
authors.affiliation: Hospital Universitário Júlio Müller, Universidade Federal de Mato Grosso, Cuiabá, MT, Brasil.
authors.forename: Cor Jesus
authors.initials: CJ
authors.lastname: Fontes
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000965:Antimony / Q000009:adverse effects* / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006562:Herpes Zoster / Q000209:etiology* / Q000821:virology; D014645:Herpesvirus 3, Human / Q000502:physiology*; D006801:Humans; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D014775:Virus Activation
chemical_list: D000981:Antiprotozoal Agents; D000965:Antimony